Literature DB >> 12576183

Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons.

Seiji Kikuchi1, Kazuyoshi Shinpo, Sachiko Tsuji, Masayoshi Takeuchi, Shoichi Yamagishi, Zenji Makita, Masaaki Niino, Ichiro Yabe, Kunio Tashiro.   

Abstract

Proteasomal dysfunction has been implicated in the pathogenesis of Parkinson's disease (PD). We examined the effect of a selective proteasomal inhibitor, epoxomicin, on primary cultured mesencephalic neurons. Exposing rat cultured mesencephalic neurons to epoxomicin for 24 h resulted in neurotoxicity in a dose-dependent manner. Epoxomicin caused mitochondrial dysfunction, reduction in reduced glutathione (GSH), and increased generation of free radicals. Neuronal damage was significantly blocked by antioxidative/GSH-augmenting agents. Epoxomicin also increased the expression of Bax and decreased that of Bcl-2, which may cause mitochondrial dysfunction and release of free radicals. Dopaminergic neurons were preferentially resistant to the toxicity of epoxomicin. Inhibiting the synthesis of tetrahydrobiopterin (BH(4)), which has been reported to have antioxidative function, increased the susceptibility of dopaminergic neurons, whereas increasing BH(4) levels protected non-dopaminergic neurons. These findings suggest that BH(4) is at least in part a contributing factor to grand the resistance to dopaminergic neurons against epoxomicin neurotoxicity. Our results suggest that proteasome inhibition causes the neurotoxicity in mesencephalic neurons, but that is not sufficient to reproduce the selective damage to dopaminergic neurons, such as that seen in PD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576183     DOI: 10.1016/s0006-8993(02)04030-1

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  12 in total

1.  Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease.

Authors:  D C Duke; L B Moran; M E Kalaitzakis; M Deprez; D T Dexter; R K B Pearce; M B Graeber
Journal:  Neurogenetics       Date:  2006-05-13       Impact factor: 2.660

2.  Insulin-like growth factor-I mediates neuroprotection in proteasome inhibition-induced cytotoxicity in SH-SY5Y cells.

Authors:  Benxu Cheng; Shivani Kaushal Maffi; Alex Anthony Martinez; Yolanda P Villarreal Acosta; Liza D Morales; James L Roberts
Journal:  Mol Cell Neurosci       Date:  2011-04-23       Impact factor: 4.314

3.  Firefly luciferase and RLuc8 exhibit differential sensitivity to oxidative stress in apoptotic cells.

Authors:  Julie Czupryna; Andrew Tsourkas
Journal:  PLoS One       Date:  2011-05-13       Impact factor: 3.240

4.  Ziram causes dopaminergic cell damage by inhibiting E1 ligase of the proteasome.

Authors:  Arthur P Chou; Nigel Maidment; Rebecka Klintenberg; John E Casida; Sharon Li; Arthur G Fitzmaurice; Pierre-Olivier Fernagut; Farzad Mortazavi; Marie-Francoise Chesselet; Jeff M Bronstein
Journal:  J Biol Chem       Date:  2008-09-25       Impact factor: 5.157

5.  Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis.

Authors:  Diogo Martins Branco; Daniela M Arduino; A Raquel Esteves; Diana F F Silva; Sandra M Cardoso; Catarina Resende Oliveira
Journal:  Front Aging Neurosci       Date:  2010-05-21       Impact factor: 5.750

6.  Proteasome inhibitors prevent oxidative stress-induced nerve cell death by a novel mechanism.

Authors:  Pamela Maher
Journal:  Biochem Pharmacol       Date:  2008-02-16       Impact factor: 5.858

7.  Insights into the effects of alpha-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson's disease: validation by cell culture data.

Authors:  Shireen Vali; Shankar J Chinta; Jun Peng; Zeba Sultana; Neetu Singh; Purushottam Sharma; S Sharada; Julie K Andersen; M M Srinivas Bharath
Journal:  Free Radic Biol Med       Date:  2008-08-08       Impact factor: 7.376

8.  Metabolism and action of proteasome inhibitors in primary human hepatocytes.

Authors:  Choon-Myung Lee; Vikas Kumar; Rochelle I Riley; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2010-09-13       Impact factor: 3.922

9.  Proteomic characterization of an isolated fraction of synthetic proteasome inhibitor (PSI)-induced inclusions in PC12 cells might offer clues to aggresomes as a cellular defensive response against proteasome inhibition by PSI.

Authors:  Xing'an Li; Yingjiu Zhang; Peng Xie; Jinhua Piao; Yihong Hu; Ming Chang; Tao Liu; Linsen Hu
Journal:  BMC Neurosci       Date:  2010-08-12       Impact factor: 3.288

10.  Elevated Hapln2 Expression Contributes to Protein Aggregation and Neurodegeneration in an Animal Model of Parkinson's Disease.

Authors:  Qinqin Wang; Qinbo Zhou; Shuzhen Zhang; Wei Shao; Yanqing Yin; Yandong Li; Jincan Hou; Xinhua Zhang; Yongshun Guo; Xiaomin Wang; Xiaosong Gu; Jiawei Zhou
Journal:  Front Aging Neurosci       Date:  2016-08-23       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.